Lexaria Bioscience Corp. (LEXX)
LEXX moved a median of -0.10% 30 minutes after news, and 0.00% by the close. How LEXX actually reacts to news — the realized, point-in-time move the market made, measured across 305 labeled events over the last three years with zero look-ahead.
LEXX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 281 |
| 30-min | -0.10% | 45% | 301 |
| 60-min | -0.45% | 43% | 303 |
| to close | 0.00% | 47% | 303 |
| Middle 50% of LEXX reactions | -1.98% to +1.35% |
|---|---|
| Median reaction (30-min) | -0.10% |
| Measured reactions | 305 |
Half of all Lexaria Bioscience Corp. news events land between -1.98% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LEXX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LEXX's baseline. Nothing else.
Recent LEXX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lexaria Announces Results from Animal Study GLP-1-A26-1 | Press release | ACCESS Newswire | +9.12% | +9.12% | |
| Form EFFECT Lexaria Bioscience Corp. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.36% | |
| GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications | Press release | ACCESS Newswire | — | +15.71% | |
| Form S-3 Lexaria Bioscience Corp. | SEC filing · Form S-3 | SEC EDGAR | — | -7.39% | |
| Form D Lexaria Bioscience Corp. | SEC filing · Form D | SEC EDGAR | +0.00% | +4.10% | |
| Lexaria Updates Financial Position | Press release | ACCESS Newswire | +8.47% | +7.17% | |
| Form 8-K Lexaria Bioscience Corp. For: Sep 07 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | -22.22% | |
| Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds | Press release | ACCESS Newswire | +0.00% | -42.14% | |
| Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds | Press release | ACCESS Newswire | -9.65% | -15.51% | |
| Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | ACCESS Newswire | +0.00% | +15.42% | |
| Form 8-K Lexaria Bioscience Corp. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +12.08% | |
| Lexaria Receives USD$2.6 Million Tax Rebate Payment | Press release | ACCESS Newswire | +0.00% | +12.08% | |
| DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 | Press release | ACCESS Newswire | +1.19% | -3.83% | |
| Form 8-K Lexaria Bioscience Corp. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | — | +8.40% | |
| Lexaria Enters a Material Transfer Agreement With PegBio | Press release | ACCESS Newswire | +2.14% | +33.22% | |
| Form 8-K Lexaria Bioscience Corp. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -8.78% | -20.74% | |
| Lexaria Announces Effective Date for Reverse Stock Split | Press release | ACCESS Newswire | -4.52% | -13.92% | |
| Form 10-Q Lexaria Bioscience Corp. For: May 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.83% | -0.49% | |
| Lexaria Updates Business Development | Press release | ACCESS Newswire | +1.79% | -0.09% | |
| Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule | Press release | ACCESS Newswire | — | -0.96% | |
| Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule | Press release | ACCESS Newswire | +0.00% | -5.40% | |
| GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand | Press release | ACCESS Newswire | -0.09% | +5.26% | |
| Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway | Press release | ACCESS Newswire | +1.54% | +2.77% | |
| Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program | Press release | ACCESS Newswire | -2.25% | +0.94% | |
| Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 | Press release | ACCESS Newswire | +0.00% | +0.57% | |
| Lexaria Bioscience Releases Second Episode of Investor Video Series | Press release | ACCESS Newswire | +0.93% | -4.37% | |
| Lexaria Updates Progress on Human Study #7 | Press release | ACCESS Newswire | +4.26% | +3.96% | |
| Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications | Press release | ACCESS Newswire | +0.00% | +9.43% | |
| Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended | Press release | ACCESS Newswire | -4.97% | -23.88% | |
| Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs | Press release | ACCESS Newswire | -0.17% | -1.84% | |
| Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales | Press release | ACCESS Newswire | -2.44% | -6.94% | |
| Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property | Press release | ACCESS Newswire | -2.88% | -0.96% | |
| Form 10-Q Lexaria Bioscience Corp. For: Feb 28 | SEC filing · Form 10-Q | SEC EDGAR | +0.27% | +6.29% | |
| Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval | Press release | ACCESS Newswire | +2.18% | +2.46% | |
| Lexaria to Begin New Human Clinical Study in GLP-1 | Press release | ACCESS Newswire | -0.38% | +6.52% | |
| Lexaria's Robust Patent Portfolio Continues to Grow | Press release | ACCESS Newswire | +3.34% | -2.02% | |
| Lexaria's Oral GLP-1 Drug Strategy Validated by Industry | Press release | ACCESS Newswire | +1.31% | +7.12% | |
| Lexaria Announces New R&D Plans for 2026 | Press release | ACCESS Newswire | +1.41% | +7.49% | |
| Form 8-K Lexaria Bioscience Corp. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.34% | |
| Lexaria Announces Positive Final Results From Human Pilot Study #5 | Press release | ACCESS Newswire | +0.71% | -8.06% | |
| Form 8-K Lexaria Bioscience Corp. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | — | +1.87% | |
| Form S-8 Lexaria Bioscience Corp. | SEC filing · Form S-8 | SEC EDGAR | +0.38% | +0.93% | |
| Lexaria Awarded Six Additional Patents | Press release | ACCESS Newswire | +0.63% | +3.43% | |
| THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point | Press release | GlobeNewswire | +0.07% | +9.66% | |
| Form EFFECT Lexaria Bioscience Corp. | SEC filing · Form EFFECT | SEC EDGAR | -1.91% | -6.28% | |
| Form 10-Q Lexaria Bioscience Corp. For: Nov 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.19% | +0.40% | |
| Lexaria Releases Annual Letter from the CEO | Press release | ACCESS Newswire | +0.78% | +10.84% | |
| Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 | Press release | ACCESS Newswire | -4.29% | +0.11% | |
| Form S-3 Lexaria Bioscience Corp. | SEC filing · Form S-3 | SEC EDGAR | -4.29% | +0.11% | |
| Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 | Press release | ACCESS Newswire | -5.51% | -4.76% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LEXX section they belong to.
Where else LEXX is measured.
LEXX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lexaria Bioscience Corp.'s median reaction calculated?
Every labeled LEXX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 305 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of LEXX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LEXX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.